1. Home
  2. AZZ vs ADPT Comparison

AZZ vs ADPT Comparison

Compare AZZ & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo AZZ Inc.

AZZ

AZZ Inc.

HOLD

Current Price

$125.34

Market Cap

3.3B

Sector

Industrials

ML Signal

HOLD

Logo Adaptive Biotechnologies Corporation

ADPT

Adaptive Biotechnologies Corporation

HOLD

Current Price

$18.17

Market Cap

2.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AZZ
ADPT
Founded
1956
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Specialties
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.3B
2.8B
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
AZZ
ADPT
Price
$125.34
$18.17
Analyst Decision
Buy
Strong Buy
Analyst Count
6
10
Target Price
$116.33
$16.70
AVG Volume (30 Days)
152.8K
2.0M
Earning Date
01-07-2026
02-05-2026
Dividend Yield
0.65%
N/A
EPS Growth
730.47
N/A
EPS
10.65
N/A
Revenue
$1,616,858,000.00
$252,754,000.00
Revenue This Year
$5.09
$50.86
Revenue Next Year
$5.31
$0.53
P/E Ratio
$11.57
N/A
Revenue Growth
1.53
42.57
52 Week Low
$70.90
$6.26
52 Week High
$127.88
$20.76

Technical Indicators

Market Signals
Indicator
AZZ
ADPT
Relative Strength Index (RSI) 67.86 54.89
Support Level $121.26 $16.55
Resistance Level $127.88 $19.42
Average True Range (ATR) 2.68 0.94
MACD -0.10 0.09
Stochastic Oscillator 75.27 69.48

Price Performance

Historical Comparison
AZZ
ADPT

About AZZ AZZ Inc.

AZZ Inc is a provider of galvanizing and a variety of metal coating solutions and coil coating solutions to a broad range of end markets in North America. The company's operating segment consists of Metal Coatings, Precoat Metals, and Infrastructure Solutions. The company generates the majority of its revenue from the Precoat Metals segment, which provides coil coating application of protective and decorative coatings and related value-added downstream processing for steel and aluminum coils. Geographically, the company generates the majority of its revenue from the United States.

About ADPT Adaptive Biotechnologies Corporation

Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).

Share on Social Networks: